

 **Mission of AABC**

The mission of the Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. They provide leadership and direction to the groups' areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new member organizations who are aligned in their commitment to research and innovation. To express interest in joining, please email co-chairs Dr. Theresa Devins (tdevins@cogrx.com) or Dr. Ornit Chiba-Falek (ornit.chibafalek@clairigene.com), or Dr. Christopher Weber (cweber@alz.org), facilitator.

 **Welcome New Members**

AABC is growing! Welcome to:

» **Fred Kim, Matthew Choung, James Rock and Tanya Xi**

AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in San Diego, CA. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer's disease. The lead asset, AR1001 is a phosphodiesterase-5 (PDE5) inhibitor being developed as an investigational oral agent for the treatment of AD. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity, demonstrating multiple mechanisms of action for disease modifying effects that may ameliorate the course of AD. AR1001-ADP3-US01 (NCT05531526) is a Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer's Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of AD through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov (<https://clinicaltrials.gov/study/NCT05531526>).

» **Adam Schultz & Ariana Myers**

Mindr is a digital platform backed by human coaches that delivers evidence-based multidomain lifestyle interventions to reduce the risk or delay the onset of symptoms of Alzheimer's disease and related dementias (ADRD). Our initial focus is on supporting those caring for a loved one with an ADRD diagnosis, to foster self-care and improve their chances of maintaining good cognitive health. Our ultimate goal is to help instill good habits for cognitive health in everyone.

 **AABC News**

AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Milestone Achievement to Advance Biomarker Development for Alzheimer's Disease and Neurodegeneration

Fujirebio Holdings Inc, its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced today the attainment of the first milestone in a strategic partnership to advance the development of biomarkers for Alzheimer's disease (AD) and other neurodegenerative conditions. This milestone marks a key achievement which provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer's disease study, POLARIS-AD.

POLARIS-AD will enroll up to 1150 participants with early Alzheimer's disease using AriBio's AR1001, a PDE5 inhibitor shown to inhibit neuron apoptosis, promote neurogenesis, increase neuroplasticity and stimulate autophagy activity to remove toxic proteins. The Phase 3 study has now expanded into South Korea, Europe, the United Kingdom and China. More information can be found [here](#).

AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China for \$770 Million USD

AriBio Co., Ltd. (AriBio), announces signing of exclusive marketing rights for AR1001, an investigational drug for early Alzheimer’s disease, in China for up to \$770 million USD.

The term consists of a non-refundable upfront payment of 120 billion KRW (approximately 90 million USD), with the total deal summing up to 5.59 billion RMB (approximately 770 million USD) inclusive of milestone payments with additional royalties. The upfront payment will be paid starting from mid-2024.

In response to the increasing Alzheimer’s disease population in China, prominent pharmaceutical companies have sought to develop safe and effective oral treatments for Alzheimer’s disease. To date, AriBio has partnered for exclusive marketing rights in South Korea with Samjin Pharmaceutical for 100 billion KRW. And now, the partnership has expanded to China, cumulating to 1.12 trillion KRW (approximately 840 million USD). Considering the market competition for Alzheimer’s drugs in China and the sales strategy, the licensee requested not to be disclosed until an agreed upon time.

The global Phase 3 clinical trial for AR1001 in early Alzheimer’s disease patients (Polaris-AD) is on-going in the United States, United Kingdom, and South Korea. Furthermore, the clinical trial is awaiting regulatory approval in China and the European Union. This study will be conducted across 180 global sites. The first patient enrollment began in the United States in December 2022, and the rest of the regions are actively enrolling.

Matthew (Jai Jun) Choung, CEO and Chairman of AriBio, stated, “This deal demonstrates our unwavering commitment to developing meaningful treatments for Alzheimer’s disease, and our partners will help position AR1001 for success in the major Asian territories. We are building momentum in our AR1001 program, as we continue to discuss with other potential partners in Asian countries, the Middle East, South America, as well as Europe and the United States.”

AriBio Co., Ltd. Announces Strategic Collaboration with Kentucky Clinical Trial Laboratory (KCTL) to Expand Alzheimer’s Disease Testing

AriBio Co., Ltd. (AriBio) announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory (KCTL) for the testing of cerebral spinal fluid (CSF) to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio. Samples from AriBio’s POLARIS-AD (AR1001-ADP3-US01) study, a global, Phase 3 early Alzheimer’s disease trial in North America, European Union, United Kingdom, and Korea can be tested for A β 42/40 ratio with the U.S. Food and Drug Administration (FDA) approved assay on the Lumipulse® system. AR1001-ADP3-US01 is a double-blind, randomized, placebo-controlled, multicenter registration trial to evaluate the efficacy and safety of AR1001 over 52 weeks of treatment in patients with early Alzheimer’s disease. The trial is using the FDA and European Medicines Agency (EMA) accepted primary endpoint Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) and secondary endpoints including Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog 13), Amsterdam-Instrumental Activities of Daily Living Questionnaire (I-IADL), Geriatric Depression Scale (GDS), Mini-Mental Status Examination (MMSE), in addition to testing for changes in CSF and plasma biomarkers. More information can be found [here](#).

bioExpert

bioExpert is organizing the sixth International Neuro4D 2025 Conference (www.neuro4d.com) from May 19-20. in Mainz Germany, located within 1 h to Frankfurt international airport. During Neuro4D 2025 we will focus on Alzheimer’s disease again, however, not excluding other neurodegenerative disease insights. We will look at the potential and ongoing initiatives using new pharmaceutical modalities like PROTACs, molecular glues, and other direct target modulating technologies.

Neuro4D brings a limited number of distinguished industry and academic speakers, poster presenters and delegates in neurodegenerative disease in direct contact, and creates lively discussions about drug discovery efforts for two full days, in a stimulating and enjoyable setting. Academic research leaders outline recent insights into the complex disease mechanisms and new pharmaceutical action modes. Biotech and international pharmaceutical companies present their developments for new treatment options, outline advantages and disadvantages of disease models and screening technologies, and present clinical outcome. Service and technology providers present their platforms and show examples of how their services contribute to the discovery of new drug candidates. By the end of the conference, all participants got to know each other, which has already seeded many productive collaborations.

Online Registration Fee for 2025 includes conference hotel accommodation from Sunday, May 18 to Tuesday, May 20 for all delegates, food and drinks during the entire two days of the event, joint social activities, and the highly praised interactive conference dinner party on Monday evening.

Members of AABC are entitled to an additional discount of 10% on the applicable rate, described on the website: www.neuro4d.com. Please state your AABC membership in the comments during registration.

Upcoming Scientific Meetings

AAIC Neuroscience Next

Feb 24-27, 2025 Online

AAIC Neuroscience Next is a global, no-cost hybrid conference that aims to support and showcase the next generation of Alzheimer's and dementia researchers and clinicians. The program is presented in a hub format that connects both global and local communities.

AAIC Advancements: APOE and Lipid Biology

March 17-18, 2025 Miami, USA and Online

AAIC Advancements: APOE & Lipid Biology will connect neuroscience researchers at all career stages to discuss the latest research on the role of APOE and lipid biology in neurodegenerative diseases, including Alzheimer's.

AAIC Satellite Symposium

May 14-15, 2025 Lima, Peru and Online

AAIC Satellite Symposium aims to convene, support and strengthen the dementia science community in Latin America. This meeting is hosted in collaboration with the Global Brain Health Institute (GBHI) and the Atlantic Fellows for Equity in Brain Health.

AAIC 2025

July 27-31 Toronto, Canada and Online

Join distinguished researchers, clinicians and dementia professionals at the largest international conference on dementia research. Share theories, breakthroughs and best practices while exploring opportunities to accelerate your work and elevate your career.

Social Media

Follow our [LinkedIn](#) We look forward to using the page to foster partnerships and communications.

Spread the Word

To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen at (ahansen@alz.org).